Infinity Pharmaceuticals Inc. (INFI) Jumps 6.47% on February 15

Equities Staff |

Infinity Pharmaceuticals Inc. (INFI) was among the biggest gainers on the Russell 2000 for Monday February 15 as the stock popped 6.47% to $5.92, representing a gain of $0.36 per share. Some 433,244 shares traded hands on 3,568 trades, compared with an average daily volume of 934,368 shares out of a total float of 49.23 million. The stock opened at $5.65 and traded with an intraday range of $5.93 to $5.32.

After today's gains, Infinity Pharmaceuticals Inc. reached a market cap of $291.44 million. Infinity Pharmaceuticals Inc. has had a trading range between $16.98 and $5.24 over the last year, and it had a 50-day SMA of $6.89 and a 200-day SMA of $9.21.

Infinity Pharmaceuticals Inc is a biopharmaceutical company engaged in discovering, developing & delivering medicines to people with difficult-to-treat diseases. Its primary product candidate is duvelisib, also known as IPI-145, an oral inhibitor.

Infinity Pharmaceuticals Inc. is based out of Cambridge, MA and has some 195 employees. Its CEO is Adelene Q. Perkins.

For a complete fundamental analysis analysis of Infinity Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for INFI. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Knightscope

Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.